[Denosumab efficient against osteoporosis. A biological drug gives new possibilities to treat a public disease].
Törring
Ove
O
Sektionen för endokrinologi, verksamhetsområde internmedicin, Södersjukhuset, Stockholm. ove.torring@ki.se
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015519:Bone Density / Q000187:drug effects; D000069448:Denosumab; D015507:Drugs, Investigational / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005598:Fractures, Spontaneous / Q000517:prevention & control; D006801:Humans; D007279:Injections, Subcutaneous; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D053245:RANK Ligand / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015507:Drugs, Investigational; D053245:RANK Ligand; D000069448:Denosumab